AP
$4.29
+1.07
(+33.07%)
As of Oct 5, 2026, 3:36 PM EDT
Price history
Apimeds Pharmaceuticals US (APUS) is trading up at $4.29 (+33.07%), as of the latest quote. It operates in the Health Care sector.
IPO: May 9, 2025 · $4.00 offering · NYSE · View IPO details →
Apimeds Pharmaceuticals US net income history (FY2023–FY2025)
Net income
| FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|
| Income statement | |||
| Operating income | −$747.4K | −$1.28M | −$11.9M |
| Net income | −$777.7K | −$1.39M | −$6.00M |
| EPS (diluted) | −$1.70 | −$1.80 | −$5.50 |
| Balance sheet | |||
| Cash and equivalents | $410.5K | $3.46K | $1.64M |
| Total assets | $422.1K | $13.1K | $164.2M |
| Total liabilities | $390.2K | $1.37M | $10.8M |
| Shareholders' equity | $31.9K | −$1.36M | $153.3M |
| Cash flow | |||
| Operating cash flow | −$627.8K | −$733.5K | −$8.93M |
| Capital expenditure | — | — | $57.3K |
| Free cash flow | — | — | −$8.98M |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$300.0K | −$275.6K | −$364.4K | −$2.66M | −$1.84M | −$7.04M | −$12.2M | −$6.28M |
| Net income | −$332.5K | −$311.6K | −$402.4K | −$2.66M | −$1.78M | −$1.16M | −$35.1M | −$20.2M |
| EPS (diluted) | −$0.40 | −$0.40 | −$0.50 | −$2.57 | −$1.40 | −$1.03 | −$22.60 | −$11.77 |
| Balance sheet | ||||||||
| Cash and equivalents | $26.6K | $3.46K | $250.4K | $8.74M | $6.99M | $1.64M | $979.5K | $278.4K |
| Total assets | — | $13.1K | $259.9K | $10.5M | $9.25M | $164.2M | $141.2M | $127.6M |
| Total liabilities | — | $1.37M | $2.02M | $809.0K | $1.09M | $10.8M | $14.7M | $21.2M |
| Shareholders' equity | −$1.05M | −$1.36M | −$1.76M | $9.74M | $8.16M | $153.3M | $126.5M | $106.4M |
| Cash flow | ||||||||
| Operating cash flow | −$186.8K | −$99.6K | −$20.3K | −$3.36M | −$1.73M | −$3.82M | −$2.07M | −$5.67M |
| Capital expenditure | — | — | — | — | $22.5K | $21.4K | $9.39K | $0 |
| Free cash flow | — | — | — | — | −$1.75M | −$3.84M | −$2.08M | −$5.67M |
From Apimeds Pharmaceuticals US's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Apimeds Pharmaceuticals US
- Headquarters
- Matawan, New Jersey From SEC filings, Oct 2026
Recent News (2)
-
GMF and FTAI Strengthen Collaboration in Engine Maintenance Business Across Asia-Pacific SINGAPORE and NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- PT Garuda Maintenance Facility Aero Asia Tbk (GMF), part of Garuda Indonesia Group, and FTAI Aviation Ltd. (Nasdaq: FTAI) have strengthened…
-
IndiGo makes historic selection of Honeywell Aerospace avionics and APUs to equip 810 new Airbus aircraft in fleet expansion Landmark agreement represents Honeywell Aerospace's largest-ever commercial equipage and service deal with India's largest airline FARNBOROUGH, United Kingdom, July 20, 2026 /PRNewswire/ -- Honeywell …
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International